Therapeutic agent for patients having human fc.gamma.riiia
CA 2481925 A1 · Owner: Niwa, Rinpei · Inventors: Okazaki, Akira; Niwa, Rinpei; Shitara, Kenya
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A drug containing, as the active ingredient an antibody composition produced , with the use of cells tolerant to a lectin recognizing a sugar chain structure in which an .alpha.-bond is formed between the 6-position of Nacetylglucosamine at the reducing end of an N-glycoside bond-type complex sugar chain and the 1-position of fucose. This drug is appropriate for patients suffering from Fc.gamma.RIIIa polymorphism who cannot be treated with a drug containing, as the active ingredient an antibody composition produced , from cells not tolerant to a lectin recognizing a sugar chain structure in which an .alpha.-bond is formed between the 6-position of N-acetylglucosamine at the reducing …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 9, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 9, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 9, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.